Horsham, PA - Kyfora Bio introduces KyFect™ - AAV, a next-generation transfection reagent engineered to improve the efficiency, scalability, and economics of adeno-associated virus (AAV) production. Designed for both early-stage research and large-scale manufacturing, KyFect™ - AAV consistently delivers high viral titers while reducing overall production costs.
As recombinant adeno-associated virus (AAV)-based therapies lead the way in gene therapy innovation, the industry faces persistent challenges related to upstream manufacturing efficiency and cost. KyFect™ - AAV addresses these challenges by leveraging Kyfora Bio’s expertise in specialty chemical manufacturing. This reagent is designed to synergistically enhance plasmid DNA binding and release at the appropriate stages of the transfection process.
A key advantage of KyFect™ - AAV is its ability to consistently deliver high viral titers, twice as high as many other reagents on the market. This enhanced performance is crucial for applications like gene therapy, where high-yield viral production is necessary for large-scale manufacturing. Process development teams can trust KyFect™ - AAV to provide the reproducible, high-quality results needed to push their projects forward.
KyFect™ - AAV also offers exceptional flexibility across a wide range of conditions. It performs consistently from small-scale shake flasks to large-scale bioreactors, minimizing the need for re-optimization during scale-up. The reagent is compatible with both adherent and suspension cell systems and supports multiple AAV serotypes, DNA concentrations, and complexation conditions—making it a versatile solution for diverse cell and gene therapy workflows.
In addition to performance and scalability, KyFect™ - AAV is designed with cost efficiency in mind. Its high transfection efficiency enables reduced plasmid DNA and reagent usage, lowering overall material costs and potentially decreasing the number of bioreactors required. These efficiencies translate into a lower cost per dose compared to conventional alternatives, benefiting both academic and commercial manufacturing environments.
Manufactured in-house in Pennsylvania, KyFect™ - AAV is a fully synthetic product, ensuring consistent quality control and a reliable supply chain. Kyfora Bio's commitment to quality means that each batch of KyFect™ - AAV meets stringent standards, reducing lead times and ensuring a steady supply for ongoing projects. The reagent will soon be available in a GMP-grade version, enabling researchers to transition seamlessly from process development to commercialization.
With its robust scalability and unmatched flexibility, KyFect™ – AAV stands to transform viral vector manufacturing and to help make life-changing gene therapies more accessible than ever before.
To learn more at Kyfora Bio, including product details and technical resources, or to read more about Kyfora Bio, visit the company's website.
About Kyfora Bio
Kyfora Bio, a subsidiary of Polysciences, Inc., specializes in high-performance transfection reagents and research materials. Based in Horsham, Pennsylvania, the company supports molecular biology, gene therapy, and drug development with innovative solutions that enhance scalability, efficiency, and reproducibility. Kyfora Bio empowers researchers by providing reliable, cost-effective products, advancing next-generation therapies, and ensuring seamless transitions from discovery to development for academic, clinical, and industrial applications.
Media Contact
Name
Kyfora Bio
Contact name
Ajmeeta Sangtani
Contact phone
1 866-992-4418
Contact address
767 Electronic Dr
City
Horsham
State
PA
Zip
19044
Country
United States
Url
https://kyforabio.com/
